Literature DB >> 23635922

Outcomes of thrombolytic treatment for acute ischemic stroke in dialysis-dependent patients in the United States.

Nauman Tariq1, Malik M Adil, Fahad Saeed, Saqib A Chaudhry, Adnan I Qureshi.   

Abstract

OBJECTIVE: To determine the outcomes of dialysis-dependent renal failure patients who had ischemic stroke and were treated with intravenous (IV) thrombolytics in the United States.
METHODS: We analyzed the data from Nationwide Inpatient Sample (2002-2009) for all thrombolytic-treated patients presenting with acute ischemic stroke with or without dialysis dependence. Patients were identified using the International Classification of Disease, Ninth Revision, Clinical Modification codes. Baseline characteristics, in-hospital complications including secondary intracerebral hemorrhage (ICH), sepsis, pneumonia, pulmonary embolism, deep venous thrombosis, urinary tract infections, and discharge outcomes (mortality, minimal disability, and moderate-to-severe disability) were compared between the groups.
RESULTS: Of the 82,142 patients with ischemic stroke who receive thrombolytic treatment, 1072 (1.3%) was dialysis dependent. The ICH rates did not differ significantly between patients with ischemic stroke with or without dialysis who received thrombolytics (5.2% versus 6.1%). The in-hospital mortality rate was higher in dialysis-dependent patients treated with thrombolytics (22% versus 11%, P≤.0001). After adjusting for age, sex, and comorbidities, dialysis dependence was associated with higher rates of in-hospital mortality in patients treated with thrombolytics (odds ratio, 1.92; 95% confidence interval, 1.33-2.78, P=.0005).
CONCLUSIONS: The 2-fold higher odds of in-hospital mortality associated with administration of IV thrombolytics in dialysis-dependent patients who present with acute ischemic stroke warrant a careful assessment of risk-benefit ratio in this population.
Copyright © 2013 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ischemic stroke; dialysis; renal failure; thrombolysis

Mesh:

Year:  2013        PMID: 23635922     DOI: 10.1016/j.jstrokecerebrovasdis.2013.03.016

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  6 in total

1.  A case of cerebral infarction during a hemodialysis procedure successfully treated with recombinant tissue plasminogen activator.

Authors:  Wei Han; Tsutomu Sakurada; Rina Hachisuka; Sayaka Kuroya; Hirofumi Sumi; Shigeki Kojima; Takeshi Okamoto; Yugo Shibagaki; Yoko Tsuchihashi; Kenji Isahaya; Naoshi Sasaki; Yasuhiro Hasegawa
Journal:  CEN Case Rep       Date:  2018-06-12

Review 2.  Treatment of Central Nervous System Complications of Renal Dialysis and Transplantation.

Authors:  Samer Dahdaleh; Paresh Malhotra
Journal:  Curr Treat Options Neurol       Date:  2019-03-11       Impact factor: 3.598

Review 3.  Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease Stages.

Authors:  Taimur Dad; Daniel E Weiner
Journal:  Semin Nephrol       Date:  2015-07       Impact factor: 5.299

Review 4.  ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II - Management of Various Cardiovascular Complications.

Authors:  Angela Yee Moon Wang; K Scott Brimble; Gillian Brunier; Stephen G Holt; Vivekanand Jha; David W Johnson; Shin-Wook Kang; Jeroen P Kooman; Mark Lambie; Chris McIntyre; Rajnish Mehrotra; Roberto Pecoits-Filho
Journal:  Perit Dial Int       Date:  2015 Jul-Aug       Impact factor: 1.756

5.  Influence of chronic kidney disease and haemodialysis on stroke outcome.

Authors:  Shrikant D Pande; Julie Morris
Journal:  Singapore Med J       Date:  2020-04-03       Impact factor: 1.858

6.  Temporal Trends in the Outcomes of Dialysis Patients Admitted With Acute Ischemic Stroke.

Authors:  Fahad Alqahtani; Chalak O Berzingi; Sami Aljohani; Mohamed Al Hajji; Anas Diab; Muhammad Alvi; Khaled Boobes; Mohamad Alkhouli
Journal:  J Am Heart Assoc       Date:  2018-06-15       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.